Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 2/20 | 1.00 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403731 | 1.00 | F2RL3 (1.00) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL27512690 | 0.89 | F2RL3 (0.80) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL19784752 | 0.88 | F2RL3 (0.79) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL7488323 | 0.88 | F2RL3 (0.78) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4478363 | 0.85 | F2RL3 (0.74) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4485942 | 0.84 | RORC (0.76) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13618430 | 0.84 | F2RL3 (0.72) | F2RL3RORCKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL23551968 | 0.82 | F2RL3 (0.69) | F2RL3KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL18427929 | 0.82 | F2RL3 (0.69) | F2RL3KDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4480347 | 0.81 | F2RL3 (0.67) | F2RL3KDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947690-A | Preparation method of indazole molecular building block and application of building block in drug synthesis | 安徽医科大学 | 2023-04-11 | — | — | CN | claimed |
| US-20180000784-A1 | PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM | THOMAS JEFFERSON UNIVERSITY (US) | 2018-01-04 | — | — | US | claimed |
| US-9789087-B2 | PAR4 inhibitor therapy for patients with PAR4 polymorphism | THOMAS JEFFERSON UNIVERSITY (US) | 2017-10-17 | — | — | US | claimed |
| US-20170035734-A1 | PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM | THOMAS JEFFERSON UNIVERSITY (US) | 2017-02-09 | — | — | US | claimed |
| WO-2009002811-A2 | THERAPEUTIC PLATELET COMPOSITIONS AND METHODS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-12-31 | — | — | WO | claimed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| CN-116003327-A | Heterocyclic compound for treating azoospermia, and preparation method and application thereof | 康复大学(筹) | 2023-04-25 | — | — | CN | disclosed |
| CN-115947690-A | Preparation method of indazole molecular building block and application of building block in drug synthesis | 安徽医科大学 | 2023-04-11 | — | — | CN | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| CN-1331076-A | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2002-01-16 | — | — | CN | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
| EP-0667345-B1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | YUNG SHIN PHARM IND CO LTD (TW) | 1999-09-29 | — | — | EP | disclosed |
| US-5574168-A | ANTICOAGULANTS | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 1996-11-12 | — | — | US | disclosed |
| EP-0667345-A1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | F2RL3 4086/4885RORC 4628/4885KDM4E 2368/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | F2RL3 2/4885RORC 3414/4885KDM4E 2420/4885 |
| US-20180000784-A1 | PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM | F2RL3, F2RL1, PARP14 | F2RL3 1/4885RORC 4770/4885KDM4E 3422/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | F2RL3 1/4885RORC 3700/4885KDM4E 1806/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | F2RL3 1/4885RORC 1774/4885KDM4E 3172/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | F2RL3 1/4885RORC 3930/4885KDM4E 1720/4885 |
| US-20170035734-A1 | PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM | F2RL3, F2RL1, PARP14 | F2RL3 1/4885RORC 4770/4885KDM4E 3422/4885 |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | F2RL3 5/4885RORC 687/4885KDM4E 4548/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | F2RL3 1/4885RORC 2752/4885KDM4E 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.